Oncology - European Medical Journal

Continue

Oncology

Filter
25 May 2016

From biologics to biosimilars

A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the…
19 Apr 2016

Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen…
EMJ
9 Mar 2016

Precision medicine for metastatic breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS…
EMJ
20 Feb 2016

Overview of a Phase I study of ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a…
EMJ
5 Feb 2016

Roles of targeted therapy and immunotherapy for gastrointestinal cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Atsushi Ohtsu, MD, PhD…
EMJ
5 Feb 2016

ESMO 2015 highlights: Putting ovarian cancer management into perspective

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes…
EMJ
5 Feb 2016

Defining ESMO Clinical Practice Guidelines at ESMO Asia 2015

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD…
EMJ
5 Feb 2016

Phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste…
We’ve noticed you’re accessing
from North/South America.